-
-
-
-
-
-
-
Journey Medical Corporation to Ring Nasdaq Stock Market Closing Bell on August 11
-
-
-
-
-
-
-
Journey Medical Corporation Announces Emrosi™ Data Analysis to be Presented at the Society of Dermatology Physician Associates (SDPA) 2025 Annual Summer Dermatology Conference
-
-
-
-
-
-
-
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
-
-
-
-
-
-
-
Journey Medical Corp (DERM) Announces U.S. FDA Approval of Emrosi
-
-
-
-
-
-
-
Journey Medical Corp (DERM) Appoints Michael C. Pearce to its Board
-
-
-
-
-
-
-
Journey Medical Corp (DERM) Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
-
-
-
-
-
-
-
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

